☆ 4.7 Article

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience

FRONTIERS IN ENDOCRINOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy

Roxana Jurubita et al.

Summary: The study demonstrated that serum anti-PLA2R antibody screening is a valuable non-invasive method for diagnosing primary MN in patients with NS. In younger patients with preserved renal function and no secondary causes of NS, a positive anti-PLA2R test can highly predict a diagnosis of primary MN.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)

Add to Collection

Article Urology & Nephrology

Membranous Nephropathy: Core Curriculum 2021

Loulwa Alsharhan et al.

Summary: Membranous nephropathy, a common cause of nephrotic syndrome, has seen rapid advancements in understanding and management over the past decade, with rituximab now at the forefront of treatment for primary disease. Monitoring circulating autoantibodies allows for more precise molecular diagnoses.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Review Urology & Nephrology

Rituximab in Membranous Nephropathy

Philipp Gauckler et al.

Summary: Membranous nephropathy is the most common cause of primary nephrotic syndrome among adults, and rituximab is now considered a first-line treatment option due to its favorable safety profile. However, questions remain about the optimal use of rituximab, and further research is needed to address these uncertainties.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Immunology

Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis

Pinyuan Dai et al.

Summary: This study compared the therapeutic effects and cost-effectiveness of different treatment options for IMN patients. It was found that cyclophosphamide + glucocorticoids was the cheapest and most effective treatment in China, while leflunomide + glucocorticoids was a cost-effective alternative. Tacrolimus + glucocorticoids had the highest remission rate despite its high cost.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Urology & Nephrology

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

Gema Fernandez-Juarez et al.

Summary: The study found that a cyclical corticosteroid-cyclophosphamide regimen was more effective in inducing persistent remission in patients with primary membranous nephropathy compared to sequential therapy with tacrolimus and rituximab, with a higher rate of complete remission. Overall, treatment with corticosteroid-cyclophosphamide resulted in a significantly greater number of patients achieving remission.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Review Immunology

Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy

Vladimir Tesar et al.

Summary: The discovery of anti-podocyte antibodies in primary membranous nephropathy has significantly impacted the diagnosis, treatment, and prognosis of this disease. Evaluation of serum levels of these antibodies allows for non-invasive diagnosis, prediction of renal outcomes, and personalized treatment. However, further research is needed to understand the relationship between anti-podocyte antibodies and cancer, the risk of MN recurrence before renal transplantation, and the implications of antibodies against minor antigens.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON

Anne-Els van de Logt et al.

KIDNEY360 (2021)

Add to Collection

Article Urology & Nephrology

Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy

Mark Canney et al.

Summary: Findings suggest that proteinuria reduction can serve as a surrogate outcome in IgA nephropathy, and quantifying the duration of proteinuria remission is valuable when estimating the risk of hard clinical endpoints.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Juergen Floege et al.

KIDNEY INTERNATIONAL (2019)

Add to Collection

Article Medicine, General & Internal

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

F. C. Fervenza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Urology & Nephrology

The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery

Anne-Els Van de Logt et al.

KIDNEY INTERNATIONAL (2019)

Add to Collection

Article Medicine, General & Internal

Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study

Simella Provatopoulou et al.

ROMANIAN JOURNAL OF INTERNAL MEDICINE (2019)

Add to Collection

Review Urology & Nephrology

Treatment of primary membranous nephropathy: where are we now?

Andrea Angioi et al.

JOURNAL OF NEPHROLOGY (2018)

Add to Collection

Review Urology & Nephrology

Epidemiology of IgA Nephropathy: A Global Perspective

Francesco Paolo Schena et al.

SEMINARS IN NEPHROLOGY (2018)

Add to Collection

Article Urology & Nephrology

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy

Jan A. J. G. van den Brand et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Add to Collection

Article Urology & Nephrology

Membranous nephropathy: New insights in therapeutic approach

Karine Dahan

NEPHROLOGIE & THERAPEUTIQUE (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies

Michael Rudnicki

BIOMED RESEARCH INTERNATIONAL (2017)

Add to Collection

Review Immunology

Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)

Antonella Radice et al.

AUTOIMMUNITY REVIEWS (2016)

Add to Collection

Article Urology & Nephrology

Rituximab as a Rescue Therapy in Patients with Glomerulonephritis

Muhammad Ziad Souqiyyeh et al.

SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION (2015)

Add to Collection

Review Urology & Nephrology

Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?

Paolo Cravedi et al.

NEPHRON CLINICAL PRACTICE (2014)

Add to Collection

Editorial Material Medicine, General & Internal

Off-label prescribing

J. Paul Seale

MEDICAL JOURNAL OF AUSTRALIA (2014)

Add to Collection

Article Pharmacology & Pharmacy

Available evidence and outcome of off-label use of rituximab in clinical practice

I. Danes et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Add to Collection

Article Urology & Nephrology

Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy

Julia M. Hofstra et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.